TheraCryf
plc
("TheraCryf", the "Company" or the "Group")
Save the date: TheraCryf Research and
Development Day - 13 June 2024
Alderley Park, 22 May 2024
- TheraCryf plc (AIM: TCF), formerly Evgen Pharma
plc, the clinical stage drug development company focussing on
oncology and neuropsychiatry, announces that it will
hold a Research and Development update event at 09:30am on 13 June
2024.
The event will be held at the offices of
Instinctif Partners located at
65 Gresham Street, London EC2V 7NQ is open to sell-side
analysts and all existing and potential shareholders. Investors and
analysts will be able attend the event in person or virtually via a
link which will be distributed to registered attendees.
The morning will comprise an update on
TheraCryf, including the Chronos acquisition and update on the
integration; discussion about the clinical programme in
glioblastoma and the preclinical programmes in neuropsychiatry. The
session will also include a discussion about market potential and
the ongoing strategy.
Speakers will include members of the TheraCryf
(and former Chronos) management and scientific team, and external
speakers including Dr Marjolein Geurts, neuro-oncologist and Dr
Wouter Vanbilloen MD, neurology resident from Erasmus University
Medical Center.
To register your attendance, please email
theracryf@instinctif.com or register via the
Investor Meet Company platform
HERE.
-
Ends-
Enquiries
|
TheraCryf plc
Dr Huw Jones, CEO
Toni Hänninen, CFO
Dr Helen Kuhlman, CBO
|
+44 (0)1625 315
090
enquiries@theracryf.com
|
|
Cavendish Capital Markets (NOMAD and
Broker)
Geoff Nash / Teddy
Whiley / Rory Sale (Corporate Finance)
Nigel Birks / Harriet Ward
(ECM)
|
+44 20 7220
0500
|
|
Instinctif Partners
Melanie Toyne-Sewell / Jack
Kincade
|
+44 207 457 2020
theracryf@Instinctif.com
|
About TheraCryf plc
TheraCryf is the clinical stage drug
development company focussing on oncology and neuropsychiatry. The
Company has a broad clinical and preclinical pipeline in
indications such as neurodevelopmental disorders, glioblastoma*,
addiction, anxiety and narcolepsy* [*orphan indications]. Its
strategy is to generate compelling data sets to proof of concept
and/or later phase II to partner its clinical programmes with
mid-size to large pharma. As well as a number of industry
partnerships with companies, including Stalicla, in
neurodevelopment disorders and has sourced programmes from
companies such as Takeda and Shire, the Company has worked with and
has ongoing collaborations with major universities, hospitals and
government organisations such as the University of Manchester,
Sapienza (Università di Roma), Kings College London and University
of Connecticut.
The Company has its headquarters and
registered office at Alderley Park, Cheshire. It is listed on AIM
in London and trades under the ticker symbol TCF.
For further information, please
visit: www.theracryf.com